Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa. , June 05, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics , Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today
Article Date
June 5, 2023
This article is featured on another website.
Go to article
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…
March 26, 2026
pharmaphorum – BIO‑Europe Spring 2026: In conversation with Marjorie Sidhoum, Vice President of Business Development and Corporate Communications at Kainova Therapeutics
March 26, 2026